Document is current
Any future updates will be listed below
-
Authors
Tana, Claudio https://orcid.org/0000-0002-9162-7866
Onan, Dilara https://orcid.org/0000-0001-9505-6135
Messina, Roberta https://orcid.org/0000-0003-4421-0432
Waliszewska-Prosół, Marta https://orcid.org/0000-0002-9074-2803
Garcia-Azorin, David https://orcid.org/0000-0002-3132-1064
Leal-Vega, Luis https://orcid.org/0000-0002-7847-413X
Coco-Martin, Maria Begoña https://orcid.org/0000-0001-9977-429X
Ornello, Raffaele https://orcid.org/0000-0001-9501-4031
Raffaelli, Bianca https://orcid.org/0000-0001-9758-1494
Souza, Marcio Nattan Portes https://orcid.org/0000-0003-4841-4491
Wells-Gatnik, William https://orcid.org/0009-0002-5564-2783
Martelletti, Paolo https://orcid.org/0000-0002-6556-4128
- License Information
-
More Information
Article History
Received: 21 April 2025
Accepted: 5 June 2025
First Online: 20 June 2025
Declarations
:
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
: Claudio Tana is a member of the Editorial Board of The Journal of Headache and Pain and Editor of the Primary Care Section of Annals of Medicine. Dilara Onan has no conflict of interests to declare. Roberta Messina reports personal fees from Eli Lilly, Lunbeck, and Bromatech for participation on advisory boards and for speaker activities. Marta Waliszewska-Prosół is a member of the Editorial Board of The Journal of Headache and Pain; reports personal fees from AbbVie, Pfizer, Polpharma and Teva for speaker activities. David Garcia-Azorin is a member of the Editorial Board of The Journal of Headache and Pain, and has received research funding from the Regional Health Administration (Gerencia Regional de Salud SACYL) in Castilla y Leon, Spain. Speaker/travel grants/ clinical trials from Teva, Abbvie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Biohaven. Luis Leal-Vega and Maria Begoña Coco-Martin have no conflict of interests to declare. Raffaele Ornello reports personal fees from Novartis, Teva, Lilly, and Pfizer, and non-financial support from AbbVie/Allergan, Lilly, Novartis, and Teva. BR received honoraria for consulting and lectures from Abbvie/Allergan, Lilly, Lundbeck, Novartis, and Teva as well as research funding from the German Research Foundation, the German Migraine and Headache Society and Novartis. Bianca Raffaelli is a member of the Editorial Board of The Journal of Headache and Pain; reports personal fees from AbbVie, Eli Lilly, Lundbeck, Novartis, Organon, Perfood and Teva for participating in advisory boards and/or speaker activities as well as research funding from Lundbeck, Novartis, Else Kröner-Fresenius-Stiftung, German Research Foundation and German Migraine and Headache Society. Marcio Nattan Portes Souza has received honoraria for oral presentations from Teva, Lilly, Novartis, Allergan/AbbVie, Sanofi, Lundbeck and Libbs. William Wells-Gatnik has no conflict of interests to declare. Paolo Martelletti is the Editor-in-Chief of The Journal of Headache and Pain and of SN Comprehensive Clinical Medicine. Paolo Martelletti and Raffaele Ornello are Editorial Board members of Neurology and Therapy. Paolo Martelletti and Raffaele Ornello were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
